Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Could Face 13% Funding Cut Under House FY '12 Appropriations Bill

Executive Summary

House Republicans' proposal to cut funding in the fiscal year 2012 Agriculture/FDA appropriations bill by 13% would cost FDA about $475 million if it applied across the board to both USDA and FDA.

You may also be interested in...

Collins Promises To Send NCATS Funding Proposal To Congress Within Weeks

National Institutes of Health Director Francis Collins expects to send, "in the fairly near future," detailed plans to Congress for shifting existing translational research projects into a new National Center for Advancing Translational Research.

Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee

FDA seems content to negotiate a user fee for biosimilars in a manner that typifies the composition of the products: similar, but not the same, as the other user fee programs.

Generic User Fee Negotiators Struggling To Meet June Deadline

FDA does not want to rush, but may consider splitting negotiators into small groups to deal with specific issues.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts